Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population–first results from a cohort study in Southern Sweden

Björk, Jonas LU ; Inghammar, Malin LU ; Moghaddassi, Mahnaz LU ; Rasmussen, Magnus LU ; Malmqvist, Ulf LU and Kahn, Fredrik LU (2022) In Infectious Diseases 54(2). p.128-133
Abstract

Background: Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings. Methods: A cohort study of 805,741 residents in Skåne county, Southern Sweden, aged 18–64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease. Results: The estimated vaccine effectiveness in preventing infection ≥7 days after second dose was 86% (95% CI 72–94%) but only 42% (95% CI 14–63%) ≥14 days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with... (More)

Background: Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings. Methods: A cohort study of 805,741 residents in Skåne county, Southern Sweden, aged 18–64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease. Results: The estimated vaccine effectiveness in preventing infection ≥7 days after second dose was 86% (95% CI 72–94%) but only 42% (95% CI 14–63%) ≥14 days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with 91% (95% CI 85–94%) effectiveness against new infection among the unvaccinated. Conclusion: A satisfactory effectiveness of BNT162b2 after the second dose was suggested, but with possibly substantially lower effect before the second dose.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
COVID-19 testing, COVID-19 vaccines, SARS-CoV2, vaccine effectiveness
in
Infectious Diseases
volume
54
issue
2
pages
128 - 133
publisher
Informa Healthcare
external identifiers
  • pmid:34586934
  • scopus:85115992228
ISSN
2374-4235
DOI
10.1080/23744235.2021.1982144
project
Improved preparedness for future pandemics and other health crises through large-scale disease surveillance
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
id
77ac9b1b-93c6-4347-b00f-8654d190a9c9
date added to LUP
2021-10-25 11:48:31
date last changed
2024-04-20 13:55:03
@article{77ac9b1b-93c6-4347-b00f-8654d190a9c9,
  abstract     = {{<p>Background: Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings. Methods: A cohort study of 805,741 residents in Skåne county, Southern Sweden, aged 18–64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease. Results: The estimated vaccine effectiveness in preventing infection ≥7 days after second dose was 86% (95% CI 72–94%) but only 42% (95% CI 14–63%) ≥14 days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with 91% (95% CI 85–94%) effectiveness against new infection among the unvaccinated. Conclusion: A satisfactory effectiveness of BNT162b2 after the second dose was suggested, but with possibly substantially lower effect before the second dose.</p>}},
  author       = {{Björk, Jonas and Inghammar, Malin and Moghaddassi, Mahnaz and Rasmussen, Magnus and Malmqvist, Ulf and Kahn, Fredrik}},
  issn         = {{2374-4235}},
  keywords     = {{COVID-19 testing; COVID-19 vaccines; SARS-CoV2; vaccine effectiveness}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{128--133}},
  publisher    = {{Informa Healthcare}},
  series       = {{Infectious Diseases}},
  title        = {{High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population–first results from a cohort study in Southern Sweden}},
  url          = {{http://dx.doi.org/10.1080/23744235.2021.1982144}},
  doi          = {{10.1080/23744235.2021.1982144}},
  volume       = {{54}},
  year         = {{2022}},
}